Zobrazeno 1 - 10
of 68
pro vyhledávání: '"William J. Mogabgab"'
Autor:
George D. Wendel, H. Hunter Handsfield, William J. Mogabgab, Edward W. Hook, William M. McCormack, Robert B. Jones
Publikováno v:
Sexually Transmitted Diseases. 20:269-273
BACKGROUND AND OBJECTIVES Cefotaxime is a third-generation cephalosporin that has in vitro activity against Neisseria gonorrhoeae, including beta-lactamase-producing strains. A single 1-g intramuscular dose is effective and is recommended by the Cent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3572a4a6dbbb0bb886301528e50eaa98
https://doi.org/10.1097/00007435-199309000-00006
https://doi.org/10.1097/00007435-199309000-00006
Autor:
Barry Smith, John M. Douglas, Z.A. Dalu, Robert B. Jones, Joseph W. Shands, Brant L. Viner, William M. McCormack, H. Hunter Handsfield, William J. Mogabgab, Edward W. Hook
Publikováno v:
The American Journal of Medicine. 94:81S-84S
In a multicenter, randomized, open, comparative trial, patients with uncomplicated gonorrhea were treated with 400 mg of oral fleroxacin or 250 mg of intramuscular ceftriaxone. A total of 458 men and 447 women were enrolled. Of these, 312 men (68%) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d90d6f18042c067a25998c9ffcec9d72
https://doi.org/10.1016/s0002-9343(20)31143-8
https://doi.org/10.1016/s0002-9343(20)31143-8
Publikováno v:
Sexually Transmitted Diseases. 19:94-98
A randomized trial was conducted to compare cefixime (400 mg or 800 mg single oral dose) with ceftriaxone (250 mg single intramuscular dose) in terms of efficacy and safety for the treatment of uncomplicated Neisseria gonorrhoeae urethritis or cervic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f540492926602a52df799ed441ccfb8
https://doi.org/10.1097/00007435-199203000-00006
https://doi.org/10.1097/00007435-199203000-00006
Autor:
William J. Mogabgab
Publikováno v:
The American Journal of Medicine. 91:S145-S149
Temafloxacin is an oral fluoroquinolone with potent in vitro activity against Neisseria gonorrhoeae. The efficacy and safety of a single dose of temafloxacin were compared with ceftriaxone, the current treatment of choice for gonorrhea, in a randomiz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f66223d0142b885c7cdb65486caf1beb
https://doi.org/10.1016/0002-9343(91)90328-u
https://doi.org/10.1016/0002-9343(91)90328-u
Publikováno v:
Chemotherapy. 36:70-76
Fifty-eight males and 34 females with nongonococcal urethritis and/or cervicitis were treated to compare the efficacy and safety of 7-day regimens of oral ofloxacin 300 mg twice daily and doxycycline hyclate 100 mg twice daily. Forty-seven patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c5702def30a20e4dc759367e0d95994
https://doi.org/10.1159/000238750
https://doi.org/10.1159/000238750
Autor:
William J. Mogabgab
Publikováno v:
The American journal of medicine. 91(6A)
Recent changes in the treatment of sexually transmitted diseases include recognition of penicillin-resistant Neisseria gonorrhoeae, identification of Chlamydia trachomatis as the leading cause of bacterial genital infection in the United States, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::772823568683834b57d970036af5dda0
https://pubmed.ncbi.nlm.nih.gov/1767802
https://pubmed.ncbi.nlm.nih.gov/1767802
Publikováno v:
Sexually transmitted diseases. 17(2)
The authors compared the safety and efficacy of 0.5 and 1.0 g of cefotetan with that of 0.25 g of ceftriaxone in a 3:3:2 randomized distribution. Of 172 patients (96 men, 76 women) aged 18-43 years who were being treated at the Delgado Venereal Disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0971b53e71a5b14bb645c9b9c4c8436d
https://pubmed.ncbi.nlm.nih.gov/2360135
https://pubmed.ncbi.nlm.nih.gov/2360135
Autor:
David C Bautnan, Bruce Pauling, William J. Mogabgab, William F LaCorte, Rose B Beville, Barbara Holmes, B. Pollock
Publikováno v:
Journal of International Medical Research. 11:269-278
Moxalactam was the single therapeutic agent used to treat a variety of infections in sixty-three patients, most of whom had serious concomitant illnesses. Fifty-three patient case reports qualified for evaluation, including those with pneumonia (8),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f18605d50a64710c9bc0c7f105c1394
https://doi.org/10.1177/030006058301100504
https://doi.org/10.1177/030006058301100504
Publikováno v:
Journal of Antimicrobial Chemotherapy. 11:153-158
Azlocillin is a semisynthetic acylureidopenicillin with increased activity against most strains of Pseudomonas aeruginosa. It was given as the sole antibacterial agent in the treatment of 21 patients with serious pulmonary, wound, bone or joint, or u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af4c0a8d8121e95a60751d7830f29e8
https://doi.org/10.1093/jac/11.suppl_b.153
https://doi.org/10.1093/jac/11.suppl_b.153
Autor:
William J. Mogabgab
Publikováno v:
Journal of International Medical Research. 2:132-136
Epicillin was used to treat 114 patients with beta-haemolytic streptococcal pharyngitis and pneumococcal pneumonia. Most patients were treated with 1 g epicillin per day and at this dosage, the response was graded as excellent in forty cases ( 35·1%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::354b70032f7aa9876ffcefd94602bd12
https://doi.org/10.1177/030006057400200205
https://doi.org/10.1177/030006057400200205